Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Launches Byetta In China To Target World's Second Largest Diabetes Market

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Eli Lilly announced Aug. 23 that the company has launched its GLP-1 agonist Byetta (exenatide) in China, and the drug will be in hospitals in first-tier cities by the end of September

You may also be interested in...



Lilly Diabetes R&D Center Arms Firm For Battle In China

Lilly’s first R&D center in China will focus on developing therapies that target the genetic profile and dietary habits of Asian diabetes patients.

New Diabetes R&D Center Arms Eli Lilly For Battle In China

Lilly’s first R&D center in China will focus on developing therapies that target the genetic profile and dietary habits of Asian diabetes patients.

Novo Nordisk Signs MOU With China's Health Ministry To Launch Patient Education Programs

Novo Nordisk's newest move to increase patient education in China will cost RMB 9 million over three years, a small price to pay to reinvigorate growth slowed by insulin price cuts.

Related Content

UsernamePublicRestriction

Register

SC072642

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel